Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovest International has secured an $8.5 million debt financing from two institutional investors, Valens Offshore SPV II and Valens US SPV I, pursuant to a note purchase agreement.
Subscribe to our email newsletter
The proceeds from the loan will be used in part to finance the analysis of unblinded data on BiovaxID, an active immunotherapeutic in a pivotal Phase III study of non-Hodgkin’s lymphoma.
Biovest issued secured promissory notes in the aggregate amount of $8.5 millions to Valens, which bear interest at prime + 2% with a six-month term. Biovest paid closing fees and costs of approximately $300,000 and a portion of the loan proceeds was used to prepay interest and principal due to Biovest’s senior secured lender, Laurus Master Fund.
Biovest also granted a royalty in the aggregate amount of 7% of worldwide net sales of the BiovaxID vaccine to Valens Offshore and Valens US pursuant to a royalty agreement.